Feb 20 |
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
|
Feb 13 |
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
|
Feb 5 |
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
|
Jan 14 |
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
|
Dec 19 |
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
|
Dec 15 |
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
|
Dec 12 |
Public Citizen petitions FDA for stricter warnings against Botox, similar drugs
|
Dec 4 |
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 8.7% CAGR over the last three years
|
Nov 18 |
Insider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ...
|
Nov 10 |
Supernus Pharmaceuticals: Derisked CNS Drug Portfolio Offers Attractive Buying Opportunity
|